Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.25 USD 3.21% Market Closed
Market Cap: 598.8m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Autolus Therapeutics PLC
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Depreciation & Amortization
$6.6m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Depreciation & Amortization
$810k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Depreciation & Amortization
ÂŁ15.6m
CAGR 3-Years
125%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Depreciation & Amortization
$7.1m
CAGR 3-Years
75%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Depreciation & Amortization
ÂŁ4.1m
CAGR 3-Years
-23%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Depreciation & Amortization
ÂŁ46.9m
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
15%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
598.8m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 56%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Depreciation & Amortization?
Depreciation & Amortization
6.6m USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Depreciation & Amortization amounts to 6.6m USD.

What is Autolus Therapeutics PLC's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
5%

Over the last year, the Depreciation & Amortization growth was -12%. The average annual Depreciation & Amortization growth rates for Autolus Therapeutics PLC have been 5% over the past three years .

Back to Top